Patent Application
20050004364
This invention relates to a new route for the preparation and purification of substituted 1,5-naphthyridine-3-carboxyamides and the pharmaceutically acceptable non-toxic salts thereof. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
The substituted 1,5-naphthyridine-3-carboxyamides that are prepared in accord with the process of the present invention are disclosed in U.S. Pat. No. 6,143,760 and PCT International Publication No. WO99/10347 A1, each of which is incorporated herein by reference in its entirety.
The present invention comprises a process of preparing a compound of the formula IV:
wherein X is hydrogen, halogen, —OR1, C1-C6 alkyl optionally substituted with up to three groups selected independently from halogen and hydroxy, or, —NR2R3; phenyl, naphthyl, 1-(5,6,7,8-tetrahydro)naphthyl or 4-(1,2-dihydro)indenyl, pyridinyl, pyrimidyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, benzofuranyl, benzothienyl, each of which is optionally substituted with up to three groups selected from halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 alkylthio, hydroxy, amino, mono or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; or, a carbocyclic group containing from 3-7 members, up to two of which members are optionally hetero atoms selected from oxygen and nitrogen, where the X carbocyclic group is optionally substituted with one or more groups selected from halogen, alkoxy, mono- or dialkylamino, sulfonamide, azacycloalkyl, cycloalkylthio, alkylthio, phenylthio, or a heterocyclic group;
In a further aspect of the present invention, said compound of formula III, which is a salt of the compound of formula IV wherein X and Y are as defined above, is prepared by treating the compound of formula IV with a strong base, MtOBs, wherein Mt is K, Na, Ce, Li or quaternary alkylammonium, and Bs is H, or (C1-C6) alkyl, preferably potassium t-butoxide.
In another aspect of the present invention, said compound of formula III is purified by filtration and recrystallization from a solvent, preferably a mixture of a water miscible ethereal solvent, and more preferably a mixture of tetrahydrofuran and water.
In a further aspect of the present invention, said compound of formula IV is prepared by treating a compound of the formula II:
wherein X is as defined above, with a primary amine YNH2 and a coupling agent, preferably 1,1-carbonyldiimidazole.
In another aspect of the present invention, said compound of formula II, wherein X is as defined above, is prepared by treating a compound of the formula I:
wherein R is C1-C6 alkyl, preferably ethyl, and X is as defined above, with (1) a strong base such as a hydroxide or an alkoxide base, preferably NaOH, KOH and KOC(CH3)3 and (2) an acid, preferably a strong acid.
In another aspect of the process of the present invention, in said acidification step (2), said compound of formula II, wherein X is as defined above, is prepared in a form whereby it may be readily and conveniently purified by filtration by adjusting the pH of the mixture resulting from treatment with base with a strong acid to about pH 1 to about pH 4, preferably about pH 2, aging at elevated temperature, cooling and filtering.
The compounds which are prepared by the process of the present invention can be described by general formulas I-IV set forth above. In a further embodiment of the process of the present invention, in any of the aforesaid general formulas I-IV, X or Y may be —NR2R3 which is a heterocyclic group such as, for example, piperidine in the case where R2 and R3 together form a C5-alkylene group. Further, R2 and R3 together may represent an alkylene or alkenylene group optionally containing up to two heteroatoms selected from nitrogen and oxygen. The resulting groups include imidazolyl, pyrrolidinyl, morpholinyl, piperazinyl, and piperidinyl.
Similarly, the —NR5R6 group in formula I above can also represent a heterocyclic group such as, for example, piperidine in the case where R5 and R6 together form a C5-alkylene group. Further, R5 and R6 together may represent an alkylene or alkenylene group optionally containing up to two heteroatoms selected from nitrogen and oxygen. The resulting groups include imidazolyl, pyrrolidinyl, morpholinyl, piperazinyl, and piperidinyl.
In certain embodiments of the invention, X represents (C1-C6) alkoxy, more particularly, (C1-C3)alkoxy. In certain specific embodiments, X is methoxy or ethoxy.
For the process of the present invention, other substituents for compounds of formulas III-IV include Y being lower alkyl, e.g., methyl or ethyl, optionally substituted with phenyl, pyridyl, or pyrimidinyl. In particular embodiments, the Y group is benzyl optionally substituted with halogen, (C1-C6)alkyl, (C1-C6)alkoxy, amino, or mono- or di(C1-C6) alkyl.
Where R2 and R3 in compounds I-IV represent optionally substituted aryl or aryl(C1-C6)alkyl, the aryl group may be phenyl, pyridyl, or pyrimidinyl, and the alkyl groups may be methyl or ethyl. Alternatively, R2 and R3 may be benzyl and phenyl.
Where X is optionally substituted C1-C6 alkyl, the alkyl group is optionally substituted methyl, ethyl, or propyl. Particular examples are perhalomethyl and trihaloethyl. Specifically, the halogens are fluorine. In a particular embodiment, substituted alkyl is 2,2,2-trifluoroethyl.
X in formulas I-IV may be an optionally substituted phenyl, naphthyl, 1-(5,6,7,8-tetrahydro)naphthyl, 4-(1,2-dihydro)indenyl, pyridinyl, pyrimidyl, isoquinolinyl, benzofuranyl, or benzothienyl group, or a 1,2,3,4-tetrahydroisoquinolinyl group.
In addition to the compounds of formulas I-IV, the process of the present invention encompasses preparation of compounds of formula IVA:
compounds of the formula IIIA:
and compounds of the formula IIA:
as well as compounds of the formula IA:
wherein substituent group X and substituent group Y when present either together or separately in any of the aforesaid general formulas IA, IIA, IIIA and IVA are defined as follows:
Specific compounds made by the process of the invention include compounds wherein pyrimidinyl(C1-C6)alkyl Y groups are 2- and 4-pyrimidinylmethyl. In particular, pyridyl(C1-C6)alkyl Y groups are 2- and 4-pyridylmethyl.
Other compounds made by the process of the invention include compounds wherein benzyl Y groups are those where R18 is amino or a substituted methyl or ethyl group. More particularly, R18 substituents are piperazin-1-yl or piperidin-1-yl substituted at the 4-position with a halogenated benzyl group.
Other specific compounds made by the process of the invention include those wherein benzyl Y groups are 4-[1-[4-(4-fluorobenzyl)piperazinyl] methyl]benzyl and 4-[1-[4-(4-fluorobenzyl)piperidinyl]methyl]benzyl.
“X” groups in formula IVA are various quinolinyl, isoquinolinyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl groups, e.g., groups of the formulas:
The following formulae represent embodiments that are prepared by the process of the present invention:
V:
wherein Y is defined above.
VI:
wherein Z represents halogen and Y is as defined above.
VII:
wherein R1 and Y are defined above.
VIII:
wherein R2, R3, and Y are defined above.
IX:
wherein R2, R8, and Y are defined above.
X:
wherein R1, G and Y are defined above.
XI:
wherein R2, R3, G, and Y are defined above.
XII:
wherein R2, R4, G, and Y are defined above.
XIII:
wherein R2, R5, G, and Y are defined above.
XIV:
wherein G and Y are defined above.
XV:
wherein R2, G, and Y are defined above.
XVI:
wherein X is defined above and U is (C1-C6)lower alkyl or (C1-C6) cycloalkyl.
XVII:
wherein X, K, and R1 are defined above.
XVIII:
wherein X and K are defined above.
XIX:
wherein X, K, and R4 are defined above.
XX:
wherein X, K, and R7 are defined above.
XXI:
wherein X, K, R14, and R15 are defined above.
XXII:
wherein X, K, and R15 are defined above.
XXIII:
wherein R10, R17 are the same or different and may be selected from hydrogen, (C1-C6)alkyl, halogen, hydroxy, lower alkoxy having 1-6 carbon atoms, or cycloalkoxy having 3-7 carbon atoms;
Other compounds prepared by the process of the present invention are encompassed by the following formulae:
XXX:
where A is C1-C6 alkylene;
Compounds of Formula XXX made in accordance with the invention are those where A is methylene, Ra is phenyl optionally substituted with methyl or ethyl, and Rb is lower alkyl. Particular compounds of Formula XXX are those where A is methylene, Ra is phenyl and Rb is C1-C3 alkyl.
XXXI:
wherein A is C1-C6 alkylene;
Other compounds of Formula XXXI made in accordance with the invention are those where A is methylene, Ra and Ra′ are independently phenyl optionally substituted with methyl or ethyl, and Rc is lower alkyl. Particular compounds of Formula XXXI are those where A is methylene, Ra is phenyl substituted in the para position with lower alkyl, Ra′ is phenyl, and Rc is C1-C3 alkyl.
XXXII:
wherein A is C1-C6 alkylene;
Compounds of Formula XXXII made in accordance with the invention are those where A is C2-C4 alkylene. Particular compounds of Formula XXXII are those where A is C2-C4 alkylene,
XXXIII:
wherein A is C1-C6 alkylene;
Compounds of Formula XXXIII made in accordance with the invention are those where A is C1-C3 alkylene. Other compounds of Formula XXXIII are those where A is C2-C4 alkylene, Rd is C1-C3 alkyl, and Rd is C2-C4 alkyl. Other compounds of Formula XXXIII are those where A is C2-C4 alkylene, Rd is C1-C3 alkyl, Re is C2-C4 alkyl, and E is nitrogen and M is methylene, E is oxygen and M is methylene or ethylene, or E and M are both nitrogen.
Still other compounds of Formula XXXIII made by the process of the invention are those where Rf is furanyl, tetrahydrofuranyl, or imidazolyl.
XXXIV:
wherein A is C1-C6 alkylene; Rd is lower alkyl optionally substituted with amino or mono- or di(C1-C6)alkylamino; and Ra′ is phenyl optionally mono-, di-, or trisubstituted with halogen, lower alkyl, lower alkoxy, or mono- or di-C1-C6 alkylamino, or mono- or di-C1-C6 alkylamino lower alkyl.
Compounds of Formula XXXIV made in accordance with the invention are those where A is C1-C3 alkylene, Ra′ is phenyl optionally substituted with methyl or ethyl, and Rd is C1-C3 alkyl. Other compounds of Formula XXXIV are where A is methylene, Ra′ is phenyl optionally substituted with methyl or ethyl, and Rd is C3-C6 alkyl. Particular compounds of Formula XXXIV are sodium, potassium, or ammonium salts of the corresponding parent compound.
Other preferred compounds of Formula XXXIV made in accordance with the invention are those where Ra is phenyl substituted with mono- or di-(C1-C6) alkylamino lower alkyl.
XXXIVa:
wherein A is C1-C6 alkylene;
Compounds of Formula XXXIVa made in accordance with the invention are those where Ra″ is imidazolyl and Rd is C1-C3 alkyl. Particular compounds of Formula XXXIVa made in accordance with the invention are those where A is methylene, Ra″ is imidazolyl, and Rd is C3-C6 alkyl.
XXXV:
wherein A is C1-C6 alkylene; and
Compounds of Formula XXXV made in accordance with the invention are those where A is C1-C3 alkylene. Particular compounds of Formula XXXV made by the process of the invention are those where A is C1-C3 alkylene, Rd is C1-C3 alkyl, and Re is C1-C3 alkyl.
XXXVI:
wherein D is nitrogen or CH;
Compounds of Formula XXXVI made in accordance with the invention are those where A is C1-C3 alkylene, Ra′ is phenyl optionally substituted with lower alkyl or halogen, and D is nitrogen. Other compounds of Formula XXXVI made in accordance with the invention are where A is methylene, Ra′ is phenyl optionally substituted with lower alkyl or halogen, D is nitrogen, and D′ is oxygen.
XXXVII:
wherein A is C1-C6 alkylene; and
Compounds of Formula XXXVII made in accordance with the invention are those where A is C1-C3 alkylene, and Ra′ is phenyl optionally substituted with lower alkyd or halogen. Other compounds of Formula XXXVII made in accordance with the invention are those where A is methylene, Ra′ is phenyl optionally substituted with lower alkyl, lower alkoxy or halogen.
XXXVIII:
wherein A is C1-C6 alkylene; and
Specific compounds of Formula XXXVIII made in accordance with the invention are those where A is C1-C3 alkylene. Other compounds of Formula XXXVIII made in accordance with the invention are those where A is C1-C3 alkylene, and Rd is C1-C3 alkyl.
wherein A is C1-C6 alkylene; and
Other compounds of Formula XXXVIIIa made in accordance with the invention are those where A is C1-C3 alkylene. Additional compounds of Formula XXXVIIIa made in accordance with the invention are those where A is C1-C3 alkylene, and Rh is C1-C3 alkyl.
XXXIX:
wherein A is C1-C6 alkylene; Rg is lower alkoxy lower alkyl; and Ra′ is phenyl optionally mono-, di-, or trisubstituted with halogen, lower alkyl, lower alkoxy, or mono- or di-C1-C6 alkylamino, or mono- or di-C1-C6 alkylamino lower alkyl.
XXXX:
wherein Rj is halogen or lower alkoxy; and Rk is lower alkyl or cycloalkyl each of which is optionally substituted with hydroxy, lower alkyl, or lower alkoxy; or Rk is phenyl (C1-C6) alkyl where the phenyl group is optionally mono-, di-, or trisubstituted with halogen, lower alkyl, lower alkoxy, or mono- or di-C1-C6 alkylamino, or mono- or di-C1-C6 alkylamino lower alkyl.
XXXXI:
wherein A is C1-C6 alkylene; Rl lower alkoxy, benzyloxy, lower alkoxy lower alkoxy, amino, or mono- or di-(C1-C6)alkylamino; and Rm is pyranyl, dihydropyranyl, tetrahydropyranyl, or hexahydropyranyl, pyridine, dihydropyridine, tetrahydropyridine, or piperidine.
Compounds of Formula XXXXI made in accordance with the invention are those where Rl is lower alkoxy and Rm is tetrahydropyranyl.
XXXXII:
wherein A is C1-C6 alkylene; Rn is lower alkoxy, benzyl, or a group of the formula:
where D is nitrogen or CH; and D′ is nitrogen or oxygen; and Ro is pyranyl, 2-or 3-thienyl; or Ro is 2-, 4-, or 5-thiazolyl or 2-, 4-, or 5-imidazolyl, each of which may be optionally substituted with lower alkyl.
XXXXIII:
wherein A is C1-C6 alkylene; Rh and Rh′ are independently hydrogen or lower alkyl, where each lower alkyl is optionally substituted with lower alkoxy; and Ra′ is phenyl optionally mono-, di-, or trisubstituted with halogen, lower alkyl, lower alkoxy, or mono- or di-C1-C6 alkyl, amino, or mono- or di-C1-C6 alkylamino lower alkyl; or Ra′ is thienyl optionally substituted with lower alkyl.
XXXXIV:
wherein A is C1-C6 alkylene; D is nitrogen or CH; D′ is nitrogen or oxygen; and Rp is lower alkyl or lower alkyl optionally substituted with lower alkoxy.
XXXXV:
wherein A is C1-C6 alkylene; X is defined as above for Formula IV; and R18 is:
Compounds of Formula XXXXV made in accordance with the invention are those where V is nitrogen and X is C1-C6 alkoxy or C1-C6 alkyl optionally substituted with up to three halogen atoms. Particular compounds of XXXXV made in accordance with the invention are those where V and V′ are nitrogen; X is C1-C3 alkoxy or C1-C3 alkyl optionally substituted with up to three halogen atoms; A″ is methylene or ethylene; and R20 is halogenated phenyl. In a specific embodiment, R20 group is 4-fluorophenyl. Other compounds of XXXXV made in accordance with the invention are those where X is 2,2,2-trifluoroethyl; V and V′ are nitrogen; R20 is halogenated phenyl; and A and A″ are methylene or ethylene.
In certain situations, compounds of Formula IV made in accordance with the invention may contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.
Representative compounds encompassed by Formula IV may be prepared by the process of the present invention include, but are not limited to the compounds in Table I and their pharmaceutically acceptable acid and base addition salts. In addition, if the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product made in accordance with the invention is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
Non-toxic pharmaceutical salts of compounds made in accordance with the invention include such salts of acids as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, sulfinic acid, formic acid, toluenesulfonic acid, methanesulfonic acid, nitric acid, benzoic acid, citric acid, tartaric acid, maleic acid, hydroiodic acid, alkanoic acids such as acetic acid, HOOC—(CH2)n—ACOOH where n is 0-4, and the like. Non-toxic pharmaceutical base addition salts of compounds made in accordance with the invention include salts of bases such as sodium, potassium, calcium, ammonium, and the like. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts.
The process of the present invention also encompasses the acylated prodrugs of the compounds of Formula IV. Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula IV.
“Lower alkyl” as used in the present invention is to encompass straight or branched chain alkyl groups having 1-6 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
By “cycloalkyl” in the present invention is meant cycloalkyl groups having 3-7 atoms such as, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
By “aryl” is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl), which is optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, heteroaryl, and hydroxy.
By “lower alkoxy” in the present invention is meant straight or branched chain alkoxy groups having 1-6 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyl, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
By “cycloalkoxy” in the present invention is meant cycloalkylalkoxy groups having 3-7 carbon atoms where cycloalkyl is defined above.
By “halogen” in the present invention is meant fluorine, bromine, chlorine, and iodine.
By “heteroaryl” (aromatic heterocycle) in the present invention is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four hetero atoms selected from nitrogen, oxygen, or sulfur. Such heteroaryl groups include, for example, thienyl, furanyl, thiazolyl, imidazolyl, (is)oxazolyl, pyridyl, pyrimidinyl, (iso)quinolinyl, naphthyridinyl, benzimidazolyl, and benzoxazolyl.
Specific examples of heteroaryl groups are the following:
wherein Q is nitrogen or —CR9; T is —NR7, oxygen, or sulfur; and R9, R10, R10′, R11, R11′, R12 are as defined above.
In particular, the process of the invention permits forming compounds wherein Y represents a carbocyclic group, and is attached to the amide nitrogen by a single bond. The result is an amide of the formula:
where X is defined as above and
represents the Y carbocyclic group.
In accordance with the process of the invention, where X is a carbocyclic group, such moiety or group includes both aromatic heterocycles (heteroaryl), unsaturated heterocyclic ring systems, and saturated heterocyclic ring systems. Examples of such groups are imidazolyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl. Certain X carbocyclic groups are linked to the parent naphthyridine moiety by a nitrogen atom in the X carbocyclic group. Thus, for example, when pyrrolidinyl is the X carbocyclic group, it is preferably a 1-pyrrolidinyl group of the formula:
In accordance with the process of the invention, where Y is a carbocyclic group, such moiety or group includes both aromatic heterocycles (heteroaryl groups), unsaturated heterocyclic ring systems, and saturated heterocyclic ring systems. Examples of such groups are imidazolyl, pyrrolidinyl, morpholinyl, piperazinyl, or piperidinyl. Preferred Y carbocyclic groups are linked to the parent naphthyridine carboxamide group by a nitrogen atom in the Y carbocyclic group. Thus, for example, when piperidinyl is the Y carbocyclic group, it is favorably a 1-piperidinyl group of the formula:
By “optionally substituted phenyl” as used herein is meant phenyl groups that are unsubstituted or substituted with up to 3 groups selected independently from halogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl, and mono- or di-lower alkylamino.
Representative compounds that may be prepared by the process of the present invention are shown below in Table 1.
The process of the present invention and the preparation of the compounds of the present invention are illustrated in Scheme 1. The preparation of the compounds of formulas II-IV are summarized in Scheme 1, wherein, unless otherwise indicated, X and Y are as defined above.
Overall, the synthetic sequence of the scheme involves saponification of the ester having structure I and acidification to form the free carboxylic acid having structure II (step 1), treatment of compound II with a primary amine and a coupling agent, preferably 1,1-carbonyldiimidazole to form an amide having structure IV (step 2) and, optionally, treatment of the amide of structure IV with a strong base such as potassium t-butoxide to form a salt having structure III (step 3), purification of the salt of structure III and then acidification of the salt of structure III to form the amide of structure IV (step 4).
In step 1 of Scheme 1 the ester having structure I is treated with an excess of strong base such as NaOH, KOH, CeOH, LiOH or other hydroxide or alkoxide base such as KOC(CH3)3, preferably NaOH or KOH in an aqueous alcoholic solvent such as methanol, ethanol or isopropanol, preferably ethanol and heated at reflux for about 1 hour to about 12 hours, with about 1 hour preferred. The solution is cooled to about 5° C. to about 25° C., with about 22° C. preferred. The solution is then gradually acidified with a strong mineral acid, preferably concentrated HCl, preferably to about pH 1 to about pH 4, most preferably, about pH 2 over a period of about 1 to about 2 hours with the final temperature being about 7° C. to about 11° C. To facilitate adjusting the pH to the preferred range, bases such KOH, NaOH, LiOH, CeOH, alkali metal alkoxides, phosphate bases, bicarbonate bases or carbonate bases may be used, with NaOH and KOH preferred. The resultant slurry is stirred for about 1 to about 5 hours at about 12° C. to about 16° C. and is then filtered, washed with water and dried under vacuum. In a preferred variation, in order to facilitate filtration, the acidified slurry is aged at elevated temperature prior to filtration, typically by heating to reflux with stirring for about 30 minutes to about 16 hours, more preferably about 1 hour to about 2 hours and is then cooled to about room temperature and filtered. The resultant product may be optionally recrystallized.
In step 2 of Scheme 1 compound II is treated with a primary amine and a coupling agent, such as thionyl chloride, oxalyl chloride or 1,1-carbonyldiimidazole (CDI) with CDI preferred, in a solvent, preferably an amide solvent such as dimethylformamide (DMF), dimethylacetamide (DMAC) or N-methylpyrrolidone (NMP), with DMF most preferred, to form an amide having structure IV. In an alternate, but less preferred route a mixed anhydride is formed by treating Compound II with an acid halide or an alkyl halo formate and a tertiary amine, preferably a trialkyl amine, to form a mixed anhydride which is treated with the primary amine to form amide IV. Amide IV may be optionally recrystallized from a solvent such as DMF or DMAC.
In step 3, the amide of structure IV is treated with a strong base, preferably a strong base such as potassium t-butoxide, by heating in a solvent, preferably an ethereal solvent containing about 3% to about 10% water, with solvents such as dioxane or tetrahydrofuran (THF) preferred, and THF most preferred, to form a salt, preferably a potassium salt, having formula III of Scheme I. The potassium salt formed in this way can be readily filtered and recrystallized from THF. The corresponding Na, Li, or Ce salts, which are less preferred, may be formed using the corresponding strong base.
In step 4, the salt corresponding to compound III, preferably the potassium salt, is slurried in water and acidified with a strong acid to a pH of about 2 to a pH of about 3.5, preferably with a mineral acid, most preferably with HCl, to form compound IV. Compound IV is readily filtered, washed with water and dried to yield highly purified compound IV.
The present invention is illustrated by the following examples, but it is not limited to the details thereof.
To a clean 1000 gallon glass lined reactor was charged 185 Kg of ethyl 6-ethoxy-4-oxo-1,4-dihydro-[1,5]-naphthyridine-3-carboxylic acid, ethyl ester, 1480 L water and 437 Kg of 2-B EtOH. To the slurry was added 150 Kg of 50% NaOH solution and 185 L water at temperatures below 40° C. The reaction was heated to reflux and held for 2 hrs. The solution was cooled to 45° C. and transferred through a preheated polish filter to a second clean 1000 gallon glass lined reactor. The empty reactor and polish filter were rinsed with 110 L water. At 25° C., the reaction filtrate was adjusted to a pH of 2-4 with filtered concentrated HCl and 50% NaOH. The slurry was heated to reflux and held for 1 hour. The slurry was allowed to stir for 1 hour at 22° C. and then filtered on a 240 L centrifuge in 4 loads. Each load was washed with 95 L filtered water and together dried in a vacuum tray dryer at 66° C. until the KF was 0.2%. This procedure afforded a 94% yield (155 Kg) of spec-free product. mp 260-268° C. Anal. Calc. for C11H10N2O4: C 56.41; H, 4.30; N, 11.96. Found: C, 56.30; H, 3.96; N, 11.93. 1H NMR (400 MHz, DMSO) 8.85 (s, 1H), 8.12 (d, J=9.2, 1H), 7.33 (d, J=9.2, 1H), 4.44 (q, J=7.2, 2H), 1.38 (t, J=7.2, 3H). 13C NMR (125 MHz, DMSO) □ 176.6, 166.5, 160.8, 142.8, 137.2, 133.1, 132.0, 118.9, 110.7, 62.1, 14.2.
A mixture of 6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acid (29 kg, 123.82 M) and 1,1-carbonyldiimidazole (22 kg, 135.64 M) in 31 gallons of DMF was heated to 90° C. under nitrogen for 2 hours during which time there was gas evolution. The mixture was cooled to 35° C. and benzyl amine (14.6 kg, 136.24 M) was added and the mixture allowed to stir at 35° C. for 2 hours, after which time the reaction was essentially complete. The mixture was then diluted with 192 gallons of water. The resultant slurry was allowed to granulate for 4 hours and then the product was isolated via filtration. The filtered product was then dried 24 hours at 45° C. to essentially constant weight. The product, N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide (38.9 kg, 97% yield) had NMR and HPLC consistent with a known sample. mp 199° C. Anal. Calc. for C18H17N3O3: C, 66.86; H, 5.30; N, 13.00. Found: C, 66.69; H, 5.18; N, 12.91. 1H NMR (500 MHz, DMSO) □12.73 (br s, 1H), 10.61 (br t, J=5.6, 1H), 8.73 (s, 1H), 8.05 (d, J=9.0, 1H), 7.35 (d, J=4.4, 2H), 7.27 (dd, J=4.4, 8.6, 2H), 7.22 (d, J=9.0, 1H), 4.56 (d, J=5.8, 2H), 4.42 (q, J=7.0, 2H), 1.35 (t, J=7.1, 3H). 13C NMR (125 MHz, DMSO) 174.5, 164.5, 160.1, 141.6, 139.3, 138.6, 132.1, 131.5, 128.4, 127.3, 126.9, 117.5, 113.6, 61.7, 42.1, 14.3.
A mixture of N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide (38 kg, 117.52 M), 80 gallons of THF, potassium t-butoxide (13.5 kg, 120.54 M) and 19 l of water was stirred to form a slurry and heated at reflux for 1 hour. The resultant solution was then filtered at a temperature maintained just below reflux. An additional 10 gallons of THF heated to 55° C. was used to rinse the filtration equipment and added to the main filtrate. An additional 80 gallons of THF was added to the filtrate which was then concentrated at atmospheric pressure to 55 gallons. The mixture was allowed to cool and granulate for 16 hours. A first crop of 27.4 kg was obtained as a wet cake. The NMR/HPLC of the product was consistent with N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide potassium salt. The mother liquor from the first crop was diluted with 55 gallons of THF, concentrated atmospherically to a final volume of 15 gallons, allowed to cool and granulate for 16 hours to yield a second crop (17.4 kg, wet cake). mp 208° C. 1H NMR (400 MHz, DMSO) □8.72 (s, 1H), 8.03 (d, J=9.2, 1H), 7.34-7.23 (m, 5H), 7.21 (d, J=9.2, 1H), 4.54 (d, J=5.2, 2H), 4.39 (q, J=7.2, 2H), 1.33 (t, J=7.2, 3H). 13C NMR (100 MHz, DMSO) 172.8, 168.8, 159.2, 150.9, 143.2, 141.2, 141.1, 140.3, 129.0, 127.9, 127.2, 114.8, 112.8, 61.5, 42.4, 15.2.
A mixture of N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide potassium salt (27.4 kg, THF wet) and 120 gallons of UPS water was stirred at 19° C. to form a slurry. The slurry was acidified with 6 L of 37% HCl yielding a pH of 2.4. The slurry was allowed to granulate 4 hours at 20° C. The product was isolated via filtration and was then washed with two 10 gallon portions of 40° C. water. The product was dried in vacuum at 45-50° C. for 48 hours under a nitrogen bleed. The product, N-benzyl-6-ethoxy4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide (16.2 kg, 42% yield) had NMR/HPLC, ash and powder x-ray indicating clinical grade purity. mp 199° C. Anal. Calc. for C18H17N3O3: C, 66.86; H, 5.30; N, 13.00. Found: C, 66.69; H, 5.18; N, 12.91. 1H NMR (500 MHz, DMSO) 12.73 (br s, 1H), 10.61 (br t, J=5.6, 1H), 8.73 (s, 1H), 8.05 (d, J=9.0, 1H), 7.35 (d, J=4.4, 2H), 7.27 (dd, J=4.4, 8.6, 2H), 7.22 (d, J=9.0, 1H), 4.56 (d, J=5.8, 2H), 4.42 (q, J=7.0, 2H), 1.35 (t, J=7.1, 3H). 13C NMR (125 MHz, DMSO) 174.5, 164.5, 160.1, 141.6, 139.3, 138.6, 132.1, 131.5, 128.4, 127.3, 126.9, 117.5, 113.6, 61.7, 42.1, 14.3.
A similar procedure was applied to the second crop of potassium salt obtained in Example 3, but a second water granulation with USP water was needed to reduce the ash levels. The final product, N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide (9.4 kg, 24% yield) was identical with the material from the first crop and had NMR/HPLC, ash and powder x-ray indicating clinical grade purity.
| Number | Date | Country | |
|---|---|---|---|
| 60473823 | May 2003 | US |
